Polyanalgesic Consensus Panel's New Treatment Guidelines Via Intraspinal Infusion for Severe Ch...(in Medicine Colts Neck NJ) -- ...),Health

Neck, NJ)

-- Michael Stanton-Hicks, MD (Cleveland Clinic, Cleveland, OH)

-- Richard L. Rauck, MD (The Center for Clinical Research,

Winston-Salem, NC)

-- James Rathmell, MD (MGH Pain Center, Boston, MA)

-- Lisa Jo Stearns, MD (Valley Cancer Pain Treatment Ctr., Division of

Valley Anesthesiology Cons., Scottsdale, AZ)

-- Mark Wallace, MD (University of California San Diego, Center for Pain

Medicine, San Diego, CA)

-- William D. Witt, MD (Interventional Pain Associates, Lexington, KY)

-- Nagy Mekhail, MD, PhD (Cleveland Clinic, Cleveland, OH)

-- Eric Buchser, MD (Center for Neuromodulation EHC, Morges, Switzerland)

-- Michael Cousins, MD (Royal North Shore Hospital, Sydney, Australia)

-- Leong Liem, MD

-- Anne Ver Donck, MD

The Polyanalgesic Consensus Panel was sponsored by Elan Pharmaceuticals, Inc.

About PRIALT

PRIALT, developed by scientists at Elan, is the synthetic equivalent of a naturally occurring conopeptide found in a marine snail known as Conus magus. PRIALT is administered through programmable microinfusion pumps that can be implanted or external and which release the drug into the fluid surrounding the spinal cord. Approved for use in 2004, PRIALT was the first intrathecal analgesic approved in the U.S. in more than two decades.

PRIALT is indicated for the management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted, and who are tolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine. PRIALT is in a class of non-opioid analgesics known as N-type calcium channel blockers.

WARNING: Severe psychiatric symptoms and neurological impairment may occur during treatment with PRIALT. Patients with a pre-existing history of psychosis should not be treated with PRIALT. All patients should be monitored frequently for e
'/>"/>